Private testosterone prescribing in the United Kingdom risks expanding hormone treatment beyond men with clear medical needs to individuals experiencing non-specific symptoms and borderline test results, according to a warning published in The BMJ today. Researchers Stephen Atkin and Eric Kilpatrick argue that commercial testing rarely accounts for the full complexity of patient care, leaving the National Health Service to manage longer-term health risks.
Commercial Market Growth and NHS Dispensing Trends
The UK testosterone replacement market reached an estimated valuation of $205 million in 2024 and projections place it at $365 million by 2032, according to data cited by News-Medical. Official figures from the NHS show that community dispensing of testosterone increased by 52% between the 2020/21 and 2024/25 periods. Concurrently, prescriptions for testosterone gel among women aged 50 and older in England experienced a tenfold rise from 2015 to 2022.
Because private prescriptions are not logged in national health databases, the exact volume of private testosterone provision remains unknown. However, Atkin and Kilpatrick point to rapid expansion indicators, including a growing number of online and private clinics. These operations often feature monthly subscription pricing ranging from £100 to £375 to cover remote consultations, home-delivered medication, and ongoing monitoring.
Diagnostic Challenges and Shared Care Burdens
Declining testosterone and libido are natural components of ageing, with up to 20% of men over 50 reporting deficiency symptoms, though fewer than 1% receive treatment through the NHS. Proper diagnosis requires time and repeated testing. The authors caution that rapid-access subscription models built around marketing non-specific symptoms are unsuited to manage this diagnostic complexity, ultimately risking unnecessary lifelong treatment.
When treating men, clinicians follow professional society guidelines featuring differing diagnostic thresholds. Consequently, NHS physicians may encounter patients who initiated testosterone therapy under more permissive private criteria. Atkin and Kilpatrick warn that longer-term risks, such as kidney and heart problems, require continuous monitoring that will likely fall to NHS resources.
Similar concerns apply to private off-label testosterone prescribing for women, primarily targeting low libido associated with menopause. Under official guidance, responsibility for care rests solely with the private clinician initiating treatment unless an NHS general practitioner formally agrees to a shared-care arrangement. In practice, patients who start treatment privately often return informally to their GPs for side effect management or blood tests, absorbing NHS workload without formal agreements.
Proposed Reporting Frameworks and Data Gaps
The authors emphasize that testosterone replacement remains an essential therapy for carefully selected patients, but stress that national data are required to address the evidence gap surrounding private prescribing habits. They call for a comprehensive reporting framework for dispensing pharmacies and private prescribers to track patient numbers, clinical indications, monitoring protocols, and transfers of care. Such a system would foster transparent prescribing practices and ensure adherence to evidence-based care while maintaining patient access.
Frequently Asked Questions About Private Testosterone Prescribing
How much does private testosterone treatment typically cost in the UK?
Private providers generally utilize subscription pricing models ranging from £100 to £375 per month, which typically cover home-delivered medication, remote consultations, and ongoing clinical monitoring.
What are the primary health risks associated with testosterone therapy?
Longer-term risks include potential kidney and heart complications that necessitate continuous monitoring, which experts warn will likely place an increased burden on NHS services.
Do private testosterone prescriptions appear in national NHS databases?
No, private prescriptions are not recorded nationally, making the total scale of private testosterone provision across the UK currently unknown.
Worth a look